Download PDF
Drug Res (Stuttg) 2018; 68(08): 436-443
DOI: 10.1055/s-0044-100186
Review
© Georg Thieme Verlag KG Stuttgart · New York

GSK-3 Inhibitors: A Double-Edged Sword? – An Update on Tideglusib

Theodore Lemuel Mathuram
1   Department of Stem Cell and Tissue Engineering, Frontier Mediville (A Unit of Frontier Lifeline and Dr. K. M. Cherian Heart Foundation), Affiliated to University of Madras, Chennai, Tamil Nadu, India
,
Lisa M. Reece
2   Sealy Center for Vaccine Development, World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA
,
Kotturathu Mammen Cherian
3   Department of Cardiothoracic Surgery, Frontier Lifeline Hospital, Chennai, Tamil Nadu, India
› Author Affiliations
Further Information

Publication History

received 31 July 2017

accepted 28 December 2017

Publication Date:
31 January 2018 (online)

Also available at
    Permissions and Reprints

Abstract

GSK-3 inhibitors are an emerging tool for clinical interventions in human diseases and represent a niche area in combinational therapy. They possess diverse facets in applications of nervous system disorders, Type 2 diabetes, regenerative medicine and cancer. However, conflicting reports suggest the controversial role of GSK-3 inhibitors in cancers. This review aims to highlight the rise of GSK-3 inhibitors as tools for molecular-targeted research and its shift to a promising drug candidate. The review also focuses on key GSK-3 inhibitors and their roles in cancer and regenerative medicine with special emphasis to tideglusib. In addition, the decisive roles of GSK-3 in various molecular pathways will be concisely reviewed. Finally, this review concludes the emergence of GSK-3 inhibitors as a ‘double-edged sword’ in the treatment against human diseases cautioning researchers about the potential ramifications of off-target pharmacological effects.

Key words

Tideglusib - GSK-3 inhibitors - cancer drugs
 

  • References

  • 1 Jope RS, Yuskaitis CJ, Beurel E. Glycogen Synthase Kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochemical research 2007; 32: 577-595
    CrossrefPubMedGoogle Scholar
  • 2 Patel P, Woodgett JR. Chapter Eight–Glycogen Synthase Kinase 3: A Kinase for All Pathways?. In: Andreas J. ed. Current Topics in Developmental Biology. Academic Press; 2017. p 277-302
    Google Scholar
  • 3 Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases. Pharmacology & Therapeutics 2015; 148: 114-131
    CrossrefPubMedGoogle Scholar
  • 4 Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells. Current Biology. 1996; 6: 1664-1669
    CrossrefPubMedGoogle Scholar
  • 5 Hong M, Chen DCR, Klein PS. et al Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3. Journal of Biological Chemistry 1997; 272: 25326-25332
    CrossrefPubMedGoogle Scholar
  • 6 Muñoz-Montaño JR, Moreno FJ, Avila J. et al. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Letters. 1997; 411: 183-188
    CrossrefPubMedGoogle Scholar
  • 7 Hampel H, Ewers M, Burger K. et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. The Journal of clinical psychiatry 2009; 70: 922-931
    CrossrefPubMedGoogle Scholar
  • 8 Macdonald A, Briggs K, Poppe M. et al. A feasibility and tolerability study of lithium in Alzheimer's disease. International Journal of Geriatric Psychiatry. 2008; 23: 704-711
    CrossrefPubMedGoogle Scholar
  • 9 Ilouz R, Kaidanovich O, Gurwitz D. et al. Inhibition of glycogen synthase kinase-3β by bivalent zinc ions: Insight into the insulin-mimetic action of zinc. Biochemical and Biophysical Research Communications 2002; 295: 102-106
    CrossrefPubMedGoogle Scholar
  • 10 Ryves WJ, Dajani R, Pearl L. et al. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochemical and Biophysical Research Communications 2002; 290: 967-972
    CrossrefPubMedGoogle Scholar
  • 11 Kroczka B, Branski P, Palucha A. et al. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull. 2001; 55: 297-300
    CrossrefPubMedGoogle Scholar
  • 12 Meijer L, Skaltsounis A-L, Magiatis P. et al. GSK-3-selective inhibitors derived from tyrian purple indirubins. Chemistry & Biology 2003; 10: 1255-1266
    CrossrefPubMedGoogle Scholar
  • 13 Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov. 2007; 6: 464-479
    CrossrefPubMedGoogle Scholar
  • 14 Sato N, Meijer L, Skaltsounis L. et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004; 10: 55-63
    CrossrefPubMedGoogle Scholar
  • 15 Meijer L, Thunnissen AM, White AW. et al. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chemistry & Biology 2000; 7: 51-63
    CrossrefPubMedGoogle Scholar
  • 16 Gompel M, Leost M, De Kier Joffe EB. et al. Meridianins, a new family of protein kinase inhibitors isolated from the Ascidian Aplidium meridianum. Bioorganic & Medicinal Chemistry Letters 2004; 14: 1703-1707
    CrossrefPubMedGoogle Scholar
  • 17 Coghlan MP, Culbert AA, Cross DAE. et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chemistry & Biology 2000; 7: 793-803
    CrossrefPubMedGoogle Scholar
  • 18 Selenica ML, Jensen HS, Larsen AK. et al. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. British Journal of Pharmacology 2007; 152: 959-979
    CrossrefPubMedGoogle Scholar
  • 19 Ying Q-L, Wray J, Nichols J. et al. The ground state of embryonic stem cell self-renewal. Nature 2008; 453: 519-523
    CrossrefPubMedGoogle Scholar
  • 20 Palm T, Bolognin S, Meiser J. et al. Rapid and robust generation of long-term self-renewing human neural stem cells with the ability to generate mature astroglia. 2015; 5: 16321
    PubMedGoogle Scholar
  • 21 Gould TD, Einat H, Bhat R. et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. International Journal of Neuropsychopharmacology. 2004; 7: 387-390
    CrossrefPubMedGoogle Scholar
  • 22 Meijer L, Leost M, Lozach O. et al. The paullones: A family of pharmacological inhibitors of cyclin-dependent kinases and glycogen synthase kinase 3. In: Pinna LA, Cohen PTW. eds. Inhibitors of Protein Kinases and Protein Phosphates. Berlin, Heidelberg. Berlin Heidelberg: Springer; 2005. p 47-64
    Google Scholar
  • 23 de Boer AS, Eggan K. A perspective on stem cell modeling of amyotrophic lateral sclerosis. Cell Cycle. 2015; 14: 3679-3688
    CrossrefPubMedGoogle Scholar
  • 24 Meijer L, Bisagni E, Legraverend M. Purine derivatives having, in particular, antiproliferative properties, and their biological uses.In Google Patents. 2001
    PubMed
  • 25 Boitano AE, Wang J, Romeo R. et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010; 329: 1345-1348
    CrossrefPubMedGoogle Scholar
  • 26 Rosa AO, Egea J, Martínez A. et al. Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: Implication of ERK1/2 and PPARγ receptors. Experimental Neurology. 2008; 212: 93-99
    CrossrefPubMedGoogle Scholar
  • 27 Aguilar-Morante D, Morales-Garcia JA, Sanz-SanCristobal M. et al. Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8. PLOS ONE 2010; 5: e13879
    CrossrefPubMedGoogle Scholar
  • 28 Martinez A, Alonso M, Castro A. et al. First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors:  Thiadiazolidinones (TDZD) as potential drugs for the treatment of alzheimer's disease. Journal of Medicinal Chemistry 2002; 45: 1292-1299
    CrossrefPubMedGoogle Scholar
  • 29 Teodoro del S. Phase IIa clinical trial on Alzheimer's disease with NP12, a GSK3 inhibitor. Alzheimer's & Dementia 2010; 6: S147
    PubMedGoogle Scholar
  • 30 Tolosa E, Litvan I, Höglinger GU. et al. for the TI A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Movement Disorders. 2014; 29: 470-478
    CrossrefPubMedGoogle Scholar
  • 31 Conde S, Pérez DI, Martínez A. et al. Thienyl and Phenyl α-Halomethyl Ketones:  New Inhibitors of Glycogen Synthase Kinase (GSK-3β) from a Library of Compound Searching. Journal of Medicinal Chemistry 2003; 46: 4631-4633
    CrossrefPubMedGoogle Scholar
  • 32 Hamann M, Alonso D, Martín-Aparicio E. et al. Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structure–Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimer’s Disease. Journal of Natural Products. 2007; 70: 1397-1405
    CrossrefPubMedGoogle Scholar
  • 33 McManus EJ, Sakamoto K, Armit LJ. et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. The EMBO Journal 2005; 24: 1571-1583
    CrossrefPubMedGoogle Scholar
  • 34 Liu P, Cheng H, Roberts TM. et al. Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer. Nature reviews Drug discovery 2009; 8: 627-644
    CrossrefPubMedGoogle Scholar
  • 35 Pap M, Cooper GM. Role of Translation Initiation Factor 2B in Control of Cell Survival by the Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3β Signaling Pathway. Molecular and Cellular Biology. 2002; 22: 578-586
    CrossrefPubMedGoogle Scholar
  • 36 Welsh GI, Miller CM, Loughlin AJ. et al. Regulation of eukaryotic initiation factor eIF2B: Glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Letters. 1998; 421: 125-130
    CrossrefPubMedGoogle Scholar
  • 37 Tejeda-Muñoz N, Robles-Flores M. Glycogen synthase kinase 3 in Wnt signaling pathway and cancer. IUBMB Life. 2015; 67: 914-922
    CrossrefPubMedGoogle Scholar
  • 38 Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 2008; 4: 68-75
    PubMedGoogle Scholar
  • 39 Magdaleno SM, Curran T. Brain development: Integrins and the Reelin pathway. Current Biology. 2001; 11: R1032-R1035
    CrossrefPubMedGoogle Scholar
  • 40 Beffert U, Morfini G, Bock HH. et al. Reelin-mediated Signaling Locally Regulates Protein Kinase B/Akt and Glycogen Synthase Kinase 3β. Journal of Biological Chemistry 2002; 277: 49958-49964
    CrossrefPubMedGoogle Scholar
  • 41 Bock HH, May P. Canonical and non-canonical reelin signaling. frontiers in cellular neuroscience 2016; 10: 166
    PubMedGoogle Scholar
  • 42 Hur E-M, Zhou F-Q. GSK3 signaling in neural development. Nature reviews Neuroscience. 2010; 11: 539-551
    PubMedGoogle Scholar
  • 43 Briscoe J, Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013; 14: 416-429
    CrossrefPubMedGoogle Scholar
  • 44 Jiang J, Hui C-C. Hedgehog signaling in development and cancer. Developmental Cell. 2008; 15: 801-812
    CrossrefPubMedGoogle Scholar
  • 45 Lai EC. Notch signaling: control of cell communication and cell fate. Development 2004; 131: 965-973
    CrossrefPubMedGoogle Scholar
  • 46 Foltz DR, Santiago MC, Berechid BE. et al. Glycogen Synthase Kinase-3β modulates notch signaling and stability. Current Biology. 2002; 12: 1006-1011
    CrossrefPubMedGoogle Scholar
  • 47 Kitisin K, Saha T, Blake T. et al. TGF-β Signaling in Development. Science's STKE 2007; 2007: cm1-cm1
    PubMedGoogle Scholar
  • 48 Lebrun J-J. The dual role of TGF in human cancer: From tumor suppression to cancer metastasis. ISRN molecular biology 2012; 2012:
    PubMed
  • 49 Guo X, Ramirez A, Waddell DS. et al. Axin and GSK3-β control Smad3 protein stability and modulate TGF-β signaling. Genes & Development 2008; 22: 106-120
    CrossrefPubMedGoogle Scholar
  • 50 Beurel E, Kornprobst M, Blivet-Van Eggelpoël M-J. et al. GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Experimental cell research 2004; 300: 354-364
    CrossrefPubMedGoogle Scholar
  • 51 Sun A, Shanmugam I, Song J. et al. Lithium suppresses cell proliferation by interrupting E2F–DNA interaction and subsequently reducing S–phase gene expression in prostate cancer. The Prostate 2007; 67: 976-988
    CrossrefPubMedGoogle Scholar
  • 52 Korur S, Huber RM, Sivasankaran B. et al. GSK3β regulates differentiation and growth arrest in glioblastoma. PLOS One 2009; 4: e7443
    CrossrefPubMedGoogle Scholar
  • 53 Ronchi A, Salaroli R, Rivetti S. et al. Lithium induces mortality in medulloblastoma cell lines. International journal of oncology 2010; 37: 745-752
    PubMedGoogle Scholar
  • 54 Hilliard TS, Gaisina IN, Muehlbauer AG. et al. Glycogen synthase kinase 3 beta inhibitors induce apoptosis in ovarian cancer cells and inhibit in vivo tumor growth. Anti-cancer drugs 2011; 22: 978-985
    PubMedGoogle Scholar
  • 55 Novetsky AP, Thompson DM, Zighelboim I. et al. Lithium and inhibition of GSK3β as a potential therapy for serous ovarian cancer. International journal of gynecological cancer: Official journal of the International Gynecological Cancer Society 2013; 23: 361-366
    CrossrefPubMedGoogle Scholar
  • 56 Li H, Huang K, Liu X. et al. Lithium chloride suppresses colorectal cancer cell survival and proliferation through ROS/GSK-3β/NF-κB signaling pathway. Oxid Med Cell Longev 2014; 2014 241864 DOI: 10.1155/2014/241864. Epub 2014 Jun 5
    CrossrefPubMedGoogle Scholar
  • 57 O’Donovan TR, Rajendran S, O’Reilly S. et al. Lithium modulates autophagy in esophageal and colorectal cancer cells and enhances the efficacy of therapeutic agents in vitro and in vivo. PLOS ONE 2015; 10: e0134676
    CrossrefPubMedGoogle Scholar
  • 58 Duffy DJ, Krstic A, Schwarzl T. et al. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling. Molecular Cancer Therapeutics. 2014; 13: 454-467
    CrossrefPubMedGoogle Scholar
  • 59 Maeng Y-S, Lee R, Lee B. et al. Lithium inhibits tumor lymphangiogenesis and metastasis through the inhibition of TGFBIp expression in cancer cells. 2016; 6: 20739
    PubMedGoogle Scholar
  • 60 Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S. et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders. The Journal of Neuroscience 2007; 27: 5766-5776
    CrossrefPubMedGoogle Scholar
  • 61 Domínguez JM, Fuertes A, Orozco L. et al. Evidence for irreversible inhibition of glycogen synthase kinase-3β by Tideglusib. Journal of Biological Chemistry 2012; 287: 893-904
    CrossrefPubMedGoogle Scholar
  • 62 Morales-Garcia JA, Luna-Medina R, Alonso-Gil S. et al. Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. ACS Chemical Neuroscience 2012; 3: 963-971
    CrossrefPubMedGoogle Scholar
  • 63 del Ser T, Steinwachs KC, Gertz HJ. et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: A pilot study. Journal of Alzheimer's Disease 2013; 33: 205-215
    PubMedGoogle Scholar
  • 64 Lovestone S, Boada M, Dubois B. et al. A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis. 2015; 45: 75-88
    PubMedGoogle Scholar
  • 65 Höglinger GU, Huppertz H-J, Wagenpfeil S. et al. for the TMRII. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Movement Disorders. 2014; 29: 479-487
    CrossrefPubMedGoogle Scholar
  • 66 Wang H, Huang S, Yan K. et al. Tideglusib, a chemical inhibitor of GSK3β, attenuates hypoxic-ischemic brain injury in neonatal mice. Biochimica et Biophysica Acta (BBA) - General Subjects 2016; 1860: 2076-2085
    PubMedGoogle Scholar
  • 67 Baruah J, Wary K. Tideglusib, an allosteric inhibitor of Glycogen Synthase Kinase (GSK)-3β increases Angiogenic activities of Endothelial Cells. The FASEB Journal 2015; 29 (1 Supplement)
    PubMed
  • 68 Armagan G, Keser A, Atalayın Ç. et al. Tideglusib protects neural stem cells against NMDA receptor overactivation. Pharmacological Reports. 2015; 67: 823-831
    CrossrefPubMedGoogle Scholar
  • 69 Swinney ZT, Haubrich BA, Xia S. et al. A four-point screening method for assessing molecular mechanism of action (MMOA) identifies tideglusib as a time-dependent inhibitor of trypanosoma brucei GSK3β. PLoS Neglected Tropical Diseases 2016; 10: e0004506
    CrossrefPubMedGoogle Scholar
  • 70 Parameswaran R, Ramakrishnan P, Moreton SA. et al. Repression of GSK3 restores NK cell cytotoxicity in AML patients. 2016; 7: 11154
    PubMedGoogle Scholar
  • 71 Mossine AV, Brooks AF, Jackson IM. et al. Synthesis of diverse 11C-labeled PET radiotracers via direct incorporation of [11C]CO2. Bioconjugate Chemistry. 2016; 27: 1382-1389
    CrossrefPubMedGoogle Scholar
  • 72 Zhou A, Lin K, Zhang S. et al. Nuclear GSK3[beta] promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. Nat Cell Biol. 2016; 18: 954-966
    CrossrefPubMedGoogle Scholar
  • 73 Mathuram TL, Ravikumar V, Reece LM. et al. Tideglusib induces apoptosis in human neuroblastoma IMR32 cells, provoking sub-G0/G1 accumulation and ROS generation. Environmental Toxicology and Pharmacology. 2016; 46: 194-205
    CrossrefPubMedGoogle Scholar
  • 74 Sun A, Li C, Chen R. et al. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. The Prostate 2016; 76: 172-183
    CrossrefPubMedGoogle Scholar
  • 75 Neves VCM, Babb R, Chandrasekaran D. et al. Promotion of natural tooth repair by small molecule GSK3 antagonists. 2017; 7: 39654
    PubMedGoogle Scholar
  • 76 Bharathy N, Svalina MN, Settelmeyer TP. et al. Preclinical testing of the glycogen synthase kinase-3beta inhibitor tideglusib for rhabdomyosarcoma. Oncotarget 2017; 8: 62976-62983
    CrossrefPubMedGoogle Scholar
  • 77 Tseng A-S, Engel FB, Keating Mark T. The GSK-3 Inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chemistry & Biology 2006; 13: 957-963
    CrossrefPubMedGoogle Scholar
  • 78 Lin C-L, Wang J-Y, Huang Y-T. et al. Wnt/β-catenin signaling modulates survival of high glucose–stressed mesangial cells. Journal of the American Society of Nephrology 2006; 17: 2812-2820
    CrossrefPubMedGoogle Scholar
  • 79 Lim JC, Kania KD, Wijesuriya H. et al. Activation of β-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. Journal of Neurochemistry 2008; 106: 1855-1865
    PubMedGoogle Scholar
  • 80 Cao H, Chu Y, Lv X. et al. GSK3 Inhibitor-BIO Regulates Proliferation of Immortalized Pancreatic Mesenchymal Stem Cells (iPMSCs). PLOS ONE 2012; 7: e31502
    CrossrefPubMedGoogle Scholar
  • 81 Soma T, Fujiwara S, Shirakata Y. et al. Hair-inducing ability of human dermal papilla cells cultured under Wnt/β-catenin signalling activation. Experimental Dermatology. 2012; 21: 307-309
    CrossrefPubMedGoogle Scholar
  • 82 Kuure S, Popsueva A, Jakobson M. et al. Glycogen Synthase Kinase-3 Inactivation and Stabilization of β-Catenin Induce Nephron Differentiation in Isolated Mouse and Rat Kidney Mesenchymes. Journal of the American Society of Nephrology 2007; 18: 1130-1139
    CrossrefPubMedGoogle Scholar
  • 83 Hoffman MD, Takahata M, Benoit DSM. 6-Bromoindirubin-3′-oxime (BIO) induces proliferation of human mesenchymal stem cells (hMSCs). In. 2011 IEEE 37th Annual Northeast Bioengineering Conference (NEBEC); 2011. p. 1-2
    PubMed
  • 84 Shen S, Xu N, Klamer G. et al. Small-molecule inhibitor of glycogen synthase kinase 3β 6-bromoindirubin-3-oxime inhibits hematopoietic regeneration in stem cell recipient mice. Stem Cells and Development 2014; 24: 724-736
    PubMedGoogle Scholar
  • 85 Liu L, Nam S, Tian Y. et al. 6-Bromoindirubin-3′-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma Cells. Cancer Research. 2011; 71: 3972-3979
    CrossrefPubMedGoogle Scholar
  • 86 Song EY, Palladinetti P, Klamer G. et al. Glycogen synthase kinase−3β inhibitors suppress leukemia cell growth. Experimental Hematology. 2010; 38: 908-921.e901
    CrossrefPubMedGoogle Scholar
  • 87 Yu A-S, Zhao L. Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3′-oxime upon ovarian cancer cells. Tumor Biology. 2016; 37: 4857-4864
    CrossrefPubMedGoogle Scholar
  • 88 Ribas J, Bettayeb K, Ferandin Y. et al. 7-Bromoindirubin-3[prime]-oxime induces caspase-independent cell death. Oncogene 2006; 25: 6304-6318
    CrossrefPubMedGoogle Scholar
  • 89 Gray JE, Infante JR, Brail LH. et al. A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Investigational New Drugs. 2015; 33: 1187-1196
    CrossrefPubMedGoogle Scholar
  • 90 Atkinson JM, Rank KB, Zeng Y. et al. Activating the Wnt/β-Catenin pathway for the treatment of melanoma – Application of LY2090314, a novel selective inhibitor of glycogen synthase kinase-3. PLOS One 2015; 10: e0125028
    CrossrefPubMedGoogle Scholar